A radically different approach for dealing with The worldwide problem of resistance to antibiotics
  • Akthelia has developed a new method for fighting infections using new compounds which act by stimulating the production of naturally occurring antimicrobial peptides (AMPs) in the body.
    • The antibacterial peptides kill bacteria, including antibiotic-resistant strains.
    • Neither the compounds nor the antibacterial peptides cause inflammation.
  • The compounds address the problem of infections in general but also those caused by multi drug resistant bacteria.
  • Akthelia is targeting gastro-intestinal infections
  • In-vivo efficacy has been established against E. coli in mice
  • In-vitro efficacy has been established against Pseudomonas aeruginosa and resistant Klebsiella pneumoniae with epithelial cells.
  • Akthelia’s concept is also applicable to other infections, including infections in veterinary medicine.
  • The new compounds can be used alone but also in combination with traditional antibiotics in order to increase efficacy and shorten treatment time.
  • Akthelia has filed three patent applications.

Differentiation over existing/competitive approaches and the supporting data

  • Broad spectrum therapy with a different mode of action from traditional antibiotics - immunomodulation that induces production of antimicrobial peptides which then kill the bacteria.
  • Pathogens are unlikely to become resistant, as production of multiple antimicrobial factors is induced. This is in contrast to traditional antibiotics, which act directly on the microbes, thus quickly selecting for resistant strains.
  • Minimal impact on microbiota.